Dulaglutide: the long-awaited new agent to treat type 2 diabetes

78 minutes to Watch
Contributor
Dr Ryan Paul
2 September 2021
Dulaglutide: the long awaited new agent to treat type 2 diabetes

Dr Paul is an academic endocrinologist at Waikato District Health Board and at the University of Waikato. He is an executive member of the New Zealand Society for the Study of Diabetes (NZSSD) and recently led the development of the NZSSD guidance on the management of type 2 diabetes in New Zealand. Dr Paul is heavily involved in teaching primary care clinicians, diabetes nurse prescribers and endocrinology trainees.

What you can expect

Presented by diabetologist Dr Ryan Paul, this recorded webinar explores:

  • When and how to use dulaglutide for type 2 diabetes
  • Advice on whether to choose funded dulaglutide or empagliflozin and when to switch between the two
  • When to advise to self-fund dulaglutide
  • The potential for dulaglutide to get patients off insulin
  • The role of dulaglutide in primary and secondary prevention of CVD.

You can find the slides from this webinar here.

More information on dulaglutide is available at:

This webinar was recorded from a live Zoom presentation hosted by Mobile Health on 25 August 2021. This video has been edited for clarity.

Professional college endorsements

This activity has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for 1.25 CME credits for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes. To claim your credits, log in to your RNZCGP dashboard to record this activity in the CME component of your CPD programme.

endorsed